Welcome to our dedicated page for PURPLE BIOTECH LTD. SEC filings (Ticker: PPBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Purple Biotech Ltd. SEC filings document foreign private issuer current reports for a clinical-stage oncology biotechnology company and its PPBT American depositary shares. Recent Form 6-K filings attach press releases and corporate presentations covering CAPTN-3, IM1240 and IM1305, preclinical and toxicology data, oncology development plans, collaboration announcements, scientific advisory activity, operating results, and risk-related forward-looking disclosures.
The filing record also reflects capital-structure and market-status matters, including ADS ratio disclosures and Nasdaq minimum bid price compliance. The company’s 6-K reports are incorporated by reference into registration statements on Form F-3 and Form S-8, linking current reports to shelf registration and equity-plan disclosure frameworks.
Purple Biotech Ltd.'s Schedule 13G/A filed by Orca Capital AG reports beneficial ownership of 306,394 American Depositary Shares (ADSs), representing 4.9% of the class on a post-offering basis. Each ADS represents 200 ordinary shares, and the ownership percentage is calculated using 6,085,450 ADSs outstanding after the issuer's registered offering.
The filing discloses that Orca has sole voting and dispositive power over all 306,394 ADSs and excludes 1,832,495 ADSs issuable upon exercise of Series B warrants held by Orca, which are subject to a 4.99% exercise blocker that prevents Orca from exercising warrants to exceed 4.99% ownership.
Purple Biotech Ltd. received a Schedule 13G filing from Orca Capital AG reporting beneficial ownership of 605,000 ADSs, representing 9.9% of the outstanding American Depositary Shares (based on 6,085,450 ADSs outstanding after the issuer's registered offering). Orca Capital states sole voting and dispositive power over these ADSs and files as a German reporting person. The filing notes that the Reporting Person holds additional pre-funded and Series B warrants that are subject to a 4.99% blocker, preventing exercise that would increase beneficial ownership above 4.99% of ordinary shares under the warrants' terms. The filing is certified by Thomas Konig, Director of Orca Capital AG.
Purple Biotech Ltd. filed a Form 6-K as a foreign private issuer, furnishing documents related to a planned financing. The exhibits include forms of a pre-funded warrant, a standard warrant, a placement agent warrant, and a securities purchase agreement, along with a press release titled “Purple Biotech Announces Pricing of Up To $18 Million Public Offering.” This indicates the company has set terms for a public offering involving ADSs and warrants.
The company states that this report does not itself constitute an offer to sell or solicit purchases of ADSs or warrants in any jurisdiction where such actions would be unlawful. The Form 6-K and its exhibits are also incorporated by reference into multiple existing Purple Biotech registration statements on Forms S-8, F-1, and F-3, making these offering documents part of those shelves and employee plan registrations.
Purple Biotech Ltd. is offering 3,055,000 ADSs (representing 611,000,000 Ordinary Shares) together with 6,110,000 Warrants to purchase up to 6,110,000 ADSs. The placement agent fee is 7.0% of gross proceeds, shown as $419,999.93, leaving estimated proceeds to the company of $5,579,704.57 before other offering expenses. The company estimates additional offering expenses (excluding placement agent fees) of approximately $215,000. Proceeds are intended to fund oncology therapeutic development and general corporate purposes. The prospectus discloses multiple historic and outstanding equity instruments and warrants with specified exercise prices and ADS equivalents, and states Ordinary Shares outstanding after this offering would be 1,806,089,801 assuming full exercise of the Pre-Funded Warrants and no exercise of the offered Warrants. The ADSs trade on Nasdaq under the symbol PPBT, and a 60-day director/officer lock-up applies. Clinical program details include NT219, with a Phase 2 investigator-initiated study initiated in June 2025.
Purple Biotech Ltd. filed a report stating that it issued a press release titled “Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai.” The filing mainly serves to furnish this press release as an exhibit for U.S. investors. The update highlights new data related to Purple Biotech’s CAPTN-3 tri-specific antibody program, IM1240, developed in collaboration with the Icahn School of Medicine at Mount Sinai.
Purple Biotech Ltd. reported that it has expanded its CAPTN-3 portfolio by adding IM1305, described as a novel tri-specific antibody targeting TROP2. This update was communicated through a press release titled “Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2”, which is furnished as an exhibit to the report. The filing formally records this development for investors and provides official access to the accompanying press release.
Purple Biotech Ltd. (PPBT) filed a Form 6-K on 23 June 2025. The sole purpose of the submission is to furnish a press release titled “Purple Biotech Announces Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress.” The press release is included as Exhibit 99.1.
The filing contains no financial statements, earnings figures, or transactional details. It merely places the press release—and all statements therein—into the U.S. public record and incorporates the document by reference into numerous outstanding registration statements (Forms S-8, F-1 and F-3) dating from 2016 through 2024. The Company also confirms that Chief Executive Officer Gil Efron signed the submission on behalf of the registrant.
Because the actual press release text is not included, investors only learn that Purple Biotech believes its CAPTN-3 tri-specific antibody platform demonstrates “significant advantages” and that these data were highlighted at the European Association for Cancer Research (EACR) 2025 Annual Congress. No quantitative efficacy results, clinical-stage milestones, or development timelines are provided in this 6-K.